Abiopharma

🔍 Opaleye Management Inc. (Executive)

Company: Alpha Cognition Inc. (ACOG)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 197 shares of Common Stock, no par value at $6.5 per share (Direct)
  Date: 2026-06-25 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,652,771.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 152,336 shares of Common Stock, no par value at $6.4017 per share (Direct)
  Date: 2026-06-26 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,805,107.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Holds 0 shares of Common Stock, no par value (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By Managed Account | shares_owned_after: 90,000.00 | Footnotes: F2

Footnotes:

• F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
• F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
• F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.335 to $6.50. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
• F4: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.